Lung Cancer
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR) (NVL-655-04)
- Details
ClinicalTrials.gov ID:
NCT0675109
Diagnosis Type:
NA
USOR Number:
- Address
,
P: